Baidu
map

J Lipid Res:CKD患者采用HDL预测心血管疾病风险并不可靠

2018-09-16 佚名 嘉音

近日,在线发表于《The Journal of Lipid Research》杂志上的一项研究表明,在慢性肾脏病(CKD)患者中,高密度脂蛋白(HDL)并不能预测患者今后的心血管疾病风险。

近日,在线发表于《The Journal of Lipid Research》杂志上的一项研究表明,在慢性肾脏病(CKD)患者中,高密度脂蛋白(HDL)并不能预测患者今后的血管疾病风险。

血管疾病(CVD)一直是导致CKD患者死亡的主要原因。CKD会显著影响患者HDL的成分和功能。但是HDL的这种异常是否会独立增加心血管事件的风险目前仍不清楚。最近萨尔州大学医学中心的Kathrin Untersteller博士和同事对526例参加CARE FOR HOME研究的非透析CKD患者的HDL的成分和功能特性是否能预测心血管结局这一问题进行了研究。

研究者们测定了高密度脂蛋白胆固醇(HDL-C)、HDL相关促炎性血清淀粉样蛋白A(SAA)的水平,以及HDL中的对氧磷酶和脂蛋白相关磷脂酶A2(Lp-PLA2)的活性;测定了清除ApoB血清的抗氧化活性。在随访的5.1±2.1年期间,153例患者发生复合心血管事件,包括心血管死亡和全因死亡。统计分析结果发现,较低的HDL-C水平,较高的SAA含量和较低的对氧磷酶活性可以预测心血管结局,而Lp-PLA2活性和ApoB清除血清抗氧化能力则无关。在校正了传统心血管和肾脏疾病危险因素后,HDL-C水平和HDL-对氧磷酶活性与心血管结局之间的相关性则不再存在,同样SAA在校正了C反应蛋白后也与心血管结局无关。

Kathrin Untersteller博士说到,“HDL-C是普通人群的心血管疾病风险的强大预测因子,相比之下,血浆HDL水平与CKD人群的心血管事件无关。”“有趣的是,随着时间的推移,血清HDL水平的逐渐增加与血液透析患者的不良预后相关,这提示了血清HDL水平在预测CKD患者心血管结局方面的缺点。”

原始出处:
Kathrin Untersteller, Sabine Meissl, Markus Trieb, et al. HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients. The Journal of Lipid Research. July 2018 59, 1256-1265.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656391, encodeId=ad921656391ac, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Dec 09 08:11:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768848, encodeId=324d1e6884875, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Tue May 21 02:11:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981710, encodeId=9f5c1981e100b, content=<a href='/topic/show?id=53782032272' target=_blank style='color:#2F92EE;'>#不可靠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20322, encryptionId=53782032272, topicName=不可靠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Jul 14 14:11:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316436, encodeId=0033131643648, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473142, encodeId=1fea14e3142f4, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498476, encodeId=843214984e61d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-12-09 bettycmoon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656391, encodeId=ad921656391ac, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Dec 09 08:11:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768848, encodeId=324d1e6884875, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Tue May 21 02:11:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981710, encodeId=9f5c1981e100b, content=<a href='/topic/show?id=53782032272' target=_blank style='color:#2F92EE;'>#不可靠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20322, encryptionId=53782032272, topicName=不可靠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Jul 14 14:11:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316436, encodeId=0033131643648, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473142, encodeId=1fea14e3142f4, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498476, encodeId=843214984e61d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656391, encodeId=ad921656391ac, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Dec 09 08:11:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768848, encodeId=324d1e6884875, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Tue May 21 02:11:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981710, encodeId=9f5c1981e100b, content=<a href='/topic/show?id=53782032272' target=_blank style='color:#2F92EE;'>#不可靠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20322, encryptionId=53782032272, topicName=不可靠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Jul 14 14:11:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316436, encodeId=0033131643648, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473142, encodeId=1fea14e3142f4, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498476, encodeId=843214984e61d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2019-07-14 许安
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656391, encodeId=ad921656391ac, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Dec 09 08:11:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768848, encodeId=324d1e6884875, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Tue May 21 02:11:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981710, encodeId=9f5c1981e100b, content=<a href='/topic/show?id=53782032272' target=_blank style='color:#2F92EE;'>#不可靠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20322, encryptionId=53782032272, topicName=不可靠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Jul 14 14:11:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316436, encodeId=0033131643648, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473142, encodeId=1fea14e3142f4, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498476, encodeId=843214984e61d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-18 ZGMFX24A
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656391, encodeId=ad921656391ac, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Dec 09 08:11:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768848, encodeId=324d1e6884875, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Tue May 21 02:11:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981710, encodeId=9f5c1981e100b, content=<a href='/topic/show?id=53782032272' target=_blank style='color:#2F92EE;'>#不可靠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20322, encryptionId=53782032272, topicName=不可靠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Jul 14 14:11:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316436, encodeId=0033131643648, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473142, encodeId=1fea14e3142f4, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498476, encodeId=843214984e61d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1656391, encodeId=ad921656391ac, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Dec 09 08:11:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768848, encodeId=324d1e6884875, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Tue May 21 02:11:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981710, encodeId=9f5c1981e100b, content=<a href='/topic/show?id=53782032272' target=_blank style='color:#2F92EE;'>#不可靠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20322, encryptionId=53782032272, topicName=不可靠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Jul 14 14:11:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316436, encodeId=0033131643648, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473142, encodeId=1fea14e3142f4, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498476, encodeId=843214984e61d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Tue Sep 18 09:11:00 CST 2018, time=2018-09-18, status=1, ipAttribution=)]

相关资讯

诊间日记:糖尿病、高血压是慢性肾脏病的主要病因!

肾小球由微血管球组成,所有对血管有损伤的因素比如糖尿病、高血压等,都会导致肾损伤。肾小球滤过膜如同人体的“地漏”,其他部位感染形成的炎性复合物容易沉积,在肾脏,人体在清除这些炎性复合物的同时损害肾脏,此外,肾小管、肾间质常常受到药物的损伤。

儿童慢性肾脏病贫血诊断与治疗专家共识

贫血是慢性肾脏病(chronic kidney disease,CKD)患儿的常见并发症,CKD 1~5期均可发生,且随肾功能下降逐渐增高,CKD 5期时贫血已非常普遍。与成人相比,儿童CKD贫血发生较早,进展速度快,不仅影响患儿体内组织氧的供应及利用,亦是其他相关并发症的发生基础,尤其是心血管并发症的独立危险因素。CKD患儿贫血与智力发育、体格发育迟滞,住院率和病死率增加密切相关。对儿童CKD贫

2018 共识声明:儿童时期发病的慢性肾脏病过渡期卫生保健

本文主要目的是为卫生保健提供者诊断慢性肾脏疾病从儿童到成人过渡期间的管理支持,从而确保为这些患者继续提供高质量的医学管理。

JCEM:家族性高胆固醇血症患者发生外周动脉疾病和慢性肾脏病的风险

由此可见,临床FH患者发生PAD和CKD风险增加,并且较低的ABI和eGFR与心肌梗塞高风险相关。因此,应对患有FH的个体进行PAD和CKD筛查,并且ABI和eGFR可用作FH管理和治疗的预后工具,以确定心肌梗塞风险极高的个体。

Diabetes Care:二甲双胍治疗2型糖尿病和慢性肾脏病效果分析!

由此可见,只要根据肾功能调整好治疗剂量,中度至重度CKD患者采用二甲双胍治疗是安全有效的。

J Hypertens:血压变异性随着慢性肾脏病分期增加而变大!

由此可见,在这个大型队列中,随着CKD分期的增加,短期收缩压变异性增加。收缩压变异性的增加可能与肾功能恶化引起的心血管风险急剧升高有关。

Baidu
map
Baidu
map
Baidu
map